ENDOCRINE, PHARMACOKINETIC AND CLINICAL-STUDIES OF THE AROMATASE INHIBITOR 3-ETHYL-3-(4-PYRIDYL)PIPERIDINE-2,6-DIONE (PYRIDOGLUTETHIMIDE) IN POSTMENOPAUSAL BREAST-CANCER PATIENTS

被引:28
作者
DOWSETT, M
MACNEILL, F
MEHTA, A
NEWTON, C
HAYNES, B
JONES, A
JARMAN, M
LONNING, P
POWLES, TJ
COOMBES, RC
机构
[1] INST CANC RES,CANC RES CAMPAIGN LABS,DRUG DEV SECT,SUTTON SM2 5NG,SURREY,ENGLAND
[2] ROYAL MARSDEN HOSP,MED BREAST UNIT,SUTTON SM2 5PX,SURREY,ENGLAND
[3] HAUKELAND HOSP,DEPT ONCOL & RADIOPHYS,N-5021 BERGEN,NORWAY
[4] ST GEORGE HOSP,CLIN ONCOL UNIT,LONDON SW17 0RE,ENGLAND
关键词
D O I
10.1038/bjc.1991.420
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aromatase inhibitor, 'pyridoglutethimide' (PyG), has been shown previously to suppress serum oestrogen levels in postmenopausal breast cancer patients and to achieve clinical responses at a dose of 500 mg twice daily (b.d.). This report gives the results of a detailed pharmacokinetic and endocrine study of PyG in ten patients. Four doses were tested at intervals of 2 weeks in the following order: 200 mg b.d., 400 mg b.d., 800 mg b.d., 1200 mg b.d. Concentration-time profiles of serum levels of PyG were curvilinear in all patients probably reflecting a saturation of metabolic enzymes. During repeat-dosing metabolism was enhanced approximately 2-fold. Plasma levels of oestradiol were significantly suppressed by the lowest dose of PyG. Although higher doses appeared to achieve greater suppression this was not statistically significant in this small group of patients. There were no significant effects at any dose on the serum levels of cortisol, aldosterone, luteinising hormone, follicle stimulating hormone, prolactin, sex hormone binding globulin or thyroid stimulating hormone. There was a dose-related increase in 17-alpha-hydroxyprogesterone levels and a dose-related decrease in levels of dehydroepiandrosterone sulphate (DHAS). The androgens DHA, testosterone and androstenedione also were significantly suppressed with at least one of the doses of PyG. Synacthen tests did not support these changes being a result of inhibition of 17,20 lyase. It is possible that they are due to enhanced clearance of DHAS. Two patients experienced no toxicity throughout the study, whilst a total of four patients were withdrawn because of side-effects: one at 400 mg b.d., two at 800 mg b.d., and one at 1200 mg b.d. The most frequent side-effects were nausea and lethargy. One patient showed an objective response to treatment.
引用
收藏
页码:887 / 894
页数:8
相关论文
共 22 条
  • [1] 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER
    COOMBES, RC
    GOSS, P
    DOWSETT, M
    GAZET, JC
    BRODIE, A
    [J]. LANCET, 1984, 2 (8414) : 1237 - 1239
  • [2] POTENCY AND SELECTIVITY OF THE NONSTEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST-CANCER PATIENTS
    DOWSETT, M
    STEIN, RC
    MEHTA, A
    COOMBES, RC
    [J]. CLINICAL ENDOCRINOLOGY, 1990, 32 (05) : 623 - 634
  • [3] DOWSETT M, 1987, CANCER RES, V47, P1957
  • [4] DOWSETT M, 1984, J CLIN ENDOCR METAB, V58, P99, DOI 10.1210/jcem-58-1-99
  • [5] BIOCHEMICAL BASIS FOR THE ANTAGONISM BETWEEN AMINOGLUTETHIMIDE AND DANAZOL IN THE ENDOCRINE TREATMENT OF BREAST-CANCER
    DOWSETT, M
    MURRAY, RML
    PITT, P
    JEFFCOATE, SL
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 1986, 23 : 277 - 284
  • [6] A STANDARDIZED MULTICENTER PROCEDURE FOR PLASMA GONADOTROPIN RADIOIMMUNOASSAY
    FERGUSON, KM
    HAYES, M
    JEFFCOATE, SL
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 1982, 19 (SEP) : 358 - 361
  • [7] ANALOGS OF AMINOGLUTETHIMIDE - SELECTIVE-INHIBITION OF AROMATASE
    FOSTER, AB
    JARMAN, M
    LEUNG, CS
    ROWLANDS, MG
    TAYLOR, GN
    PLEVEY, RG
    SAMPSON, P
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (02) : 200 - 204
  • [8] FOSTER AB, 1985, Patent No. 2151226
  • [9] METABOLIC-CLEARANCE RATE (MCR) OF DEHYDROEPIANDROSTERONE SULFATE (DS), ITS METABOLISM TO DEHYDROEPIANDROSTERONE, ANDROSTENEDIONE, TESTOSTERONE, AND DIHYDROTESTOSTERONE, AND THE EFFECT OF INCREASED PLASMA DS CONCENTRATION ON DS MCR IN NORMAL WOMEN
    HANING, RV
    CHABOT, M
    FLOOD, CA
    HACKETT, R
    LONGCOPE, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 69 (05) : 1047 - 1052
  • [10] AMINOGLUTETHIMIDE DOSE AND HORMONE SUPPRESSION IN ADVANCED BREAST-CANCER
    HARRIS, AL
    DOWSETT, M
    JEFFCOATE, SL
    SMITH, IE
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (04): : 493 - 498